Previous 10 | Next 10 |
Image source: The Motley Fool. Arqule Inc (NASDAQ: ARQL) Q3 2019 Earnings Call Oct 30, 2019 , 9:00 a.m. ET Operator Continue reading
ArQule, Inc. (ARQL) Q3 2019 Earnings Conference Call October 30, 2019, 09:00 AM ET Company Participants Marc Schegerin - CFO Paolo Pucci - CEO Peter Lawrence - President and COO Brian Schwartz - Head of R&D Conference Call Participants Jonathan Chang - SVB Leerink V...
ArQule (NASDAQ: ARQL ): Q3 GAAP EPS of -$0.09 in-line. More news on: ArQule, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Conference call scheduled today at 9:00 a.m. ET ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2019. For the quarter ended September 30, 2019, the Company reported a net loss of $10.7 million, or $0.09 per basic share, compared with net...
Data from a phase 1 clinical trial suggest that circulating tumor DNA (ctDNA) may serve as a reliable biomarker of tumor mutational status and could be used to predict treatment response Preclinical work demonstrates treatment with ARQ 751 in combination with a variety of therapeutic a...
Market Pulse Biotech and pharmaceutical groups have struggled immensely over the past two months as unique issues affecting the industry have become more dominant. The general market skittishness over rate policy and tariffs have also contributed to the woes. However, with the broader mark...
Treatment with miransertib prevents formation of new PIK3CA-driven vascular malformations and leads to regression of existing PIK3CA-driven vascular malformations in experimental mouse model ArQule , Inc. (Nasdaq: ARQL), today announced preclinical data demonstrating the potential for...
ArQule , Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter of 2019 before the market opens on Wednesday, October 30, 2019. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a gener...
Two poster presentations on ARQ 751 will highlight data from the phase 1 trial, as well as preclinical studies demonstrating the potential of ARQ 751 in combination with various therapeutic agents ArQule , Inc. (Nasdaq: ARQL) today announced that it will be presenting data on the comp...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to...
News, Short Squeeze, Breakout and More Instantly...
What stock will go up the most in 2020? We'd all like to know that one. And it's a question that's a lot easier to ask than to answer. Let's start by looking at the top 10 stocks of 2019 for clues. The No. 1 stock of 2019, Axsome Therapeutics , had a staggering 3,578% retu...
Dollar Tree (NASDAQ: DLTR) stock was pummeled in November after its earnings report resulted in the deep discounter reducing its sales outlook for the third consecutive quarter and lowering its profit forecast. Shares trade at the same level now as they did a year ago, meaning inves...
The top 10 stocks of 2019 are an interesting group. You might think tech stocks would dominate the upper echelon of equities, but you'd be wrong. As we saw in the IPO market , individual healthcare stocks actually had the strongest returns last year. Seven biotech companies made our list, inc...